ACADIA Pharmaceuticals Inc.
ACAD
$25.13
-$0.32-1.26%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 8.29% | -5.89% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 8.29% | -5.89% | |||
| Cost of Revenue | 0.03% | -19.49% | |||
| Gross Profit | 13.88% | 6.27% | |||
| SG&A Expenses | 5.65% | -2.85% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.18% | -10.92% | |||
| Operating Income | 67.83% | 176.04% | |||
| Income Before Tax | 44.75% | -82.76% | |||
| Income Tax Expenses | 54.06% | -49.31% | |||
| Earnings from Continuing Operations | 40.44% | -86.79% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 40.44% | -86.79% | |||
| EBIT | 67.83% | 176.04% | |||
| EBITDA | 58.76% | 82.27% | |||
| EPS Basic | 39.63% | -86.81% | |||
| Normalized Basic EPS | 43.80% | 90.31% | |||
| EPS Diluted | 44.45% | -87.19% | |||
| Normalized Diluted EPS | 43.96% | 89.56% | |||
| Average Basic Shares Outstanding | 0.61% | 0.16% | |||
| Average Diluted Shares Outstanding | 0.60% | 0.58% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||